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Summary
Background Optimum management of clinically localised prostate cancer presents unique challenges because of 
the highly variable and often indolent natural history of the disease. To predict disease aggressiveness, clinicians 
combine clinical variables to create prognostic models, but the models have limited accuracy. We assessed the 
prognostic value of a predeﬁ ned cell cycle progression (CCP) score in two cohorts of patients with prostate cancer.
Methods We measured the expression of 31 genes involved in CCP with quantitative RT-PCR on RNA extracted from 
formalin-ﬁ xed paraﬃ  n-embedded tumour samples, and created a predeﬁ ned score and assessed its usefulness in the 
prediction of disease outcome. The signature was assessed retrospectively in a cohort of patients from the USA who 
had undergone radical prostatectomy, and in a cohort of randomly selected men with clinically localised prostate 
cancer diagnosed by use of a transurethral resection of the prostate (TURP) in the UK who were managed 
conservatively. The primary endpoint was time to biochemical recurrence for the cohort of patients who had radical 
prostatectomy, and time to death from prostate cancer for the TURP cohort.
Findings After prostatectomy, the CCP score was useful for predicting biochemical recurrence in the univariate 
analysis (hazard ratio for a 1-unit change [doubling] in CCP 1·89; 95% CI 1·54–2·31; p=5·6×10–⁹) and the best 
multivariate analysis (1·77, 1·40–2·22; p=4·3×10–⁶). In the best predictive model (ﬁ nal multivariate analysis), the CCP 
score and prostate-speciﬁ c antigen (PSA) concentration were the most important variables and were more signiﬁ cant 
than any other clinical variable. In the TURP cohort, the CCP score was the most important variable for prediction of 
time to death from prostate cancer in both univariate analysis (2·92, 2·38–3·57, p=6·1×10–²²) and the ﬁ nal multivariate 
analysis (2·57, 1·93–3·43; p=8·2×10–¹¹), and was stronger than all other prognostic factors, although PSA concentration 
also added useful information. Heterogeneity in the hazard ratio for the CCP score was not noted in any case for any 
clinical variables.
Interpretation The results of this study provide strong evidence that the CCP score is a robust prognostic marker, 
which, after additional validation, could have an essential role in determining the appropriate treatment for patients 
with prostate cancer.
Funding Cancer Research UK, Queen Mary University of London, Orchid Appeal, US National Institutes of Health, 
and Koch Foundation.
Introduction
Prostate cancer is a common diagnosis, especially when 
prostate-speciﬁ c antigen (PSA) screening is used,1 and 
its natural history is highly variable and diﬃ  cult to 
predict. Some men have indolent disease that can be 
safely followed without immediate treatment, whereas 
others have aggressive cancer and need immediate 
intervention. Accurate prediction of disease behaviour 
is critical because radical treatment is associated with 
high morbidity. Indiscriminate overtreatment of 
indolent disease is a serious problem, which has led to 
calls for a conservative approach to treatment of prostate 
cancer. However, this approach is not without 
consequences because prostate cancer is already a 
common form of cancer death in men in developed 
countries.1 Furthermore, conservative management can 
lead to considerable anxiety, especially when the clinical 
outcome is uncertain.
The problems associated with an uncertain prognosis 
have been exacerbated by the introduction of PSA screening 
in some countries, leading to an increase in reported 
incidence but having little eﬀ ect on mortality rates.2,3 In 
autopsy series, histologically proven prostate cancer was 
identiﬁ ed in about 40% of men older than 50 years who 
died of other causes.4,5 This percentage is about ten times 
higher than the lifetime risk of dying from prostate cancer 
in the western world,1 indicating that intensive screening 
is likely to increase the detection of indolent disease.
Clinical variables like Gleason score, tumour stage, 
margin status, and PSA concentration, in various 
combinations, have been used in models for prediction 
of disease outcome.6–9 In the most favourable of clinical 
Articles
246 www.thelancet.com/oncology   Vol 12   March 2011
settings (ie, after surgical resection), these prognostic 
models are about 75–85% accurate,10 but are less accurate 
in conservatively treated patients.11–13 Many groups tried 
to develop tumour-derived RNA expression markers to 
enhance the predictive power of clinical variables.14–20 
However, these studies have achieved only limited 
success and have not changed clinical care.
By contrast, tumour-derived RNA expression signatures21 
have proven to have prognostic value in breast cancer and 
have changed clinical care.22–27 Although these signatures 
have very few genes in common, they perform similarly in 
terms of prediction of disease recurrence.28 This apparent 
inconsistency can be reconciled by noting that the predictive 
power of each signature is generated primarily from genes 
that have their expression regulated as a function of cell 
cycle progression (CCP).29 CCP genes were originally 
identiﬁ ed as having RNA expression that ﬂ uctuated as cells 
progressed through the diﬀ erent stages of the cell cycle.30
Since the expression of CCP genes is likely to represent 
a fundamental aspect of tumour biology, these genes 
might be useful for prediction of outcome in prostate 
cancer. We therefore selected a set of CCP genes and 
retrospectively tested their prognostic value in prediction 
of disease outcome using a predeﬁ ned score, in a cohort 
of patients with prostate cancer who had been treated 
with radical prostatectomy and in a cohort of 
conservatively treated patients.
Methods
CCP gene selection
To reliably generate expression data from formalin-ﬁ xed 
paraﬃ  n-embedded (FFPE) tissue, we selected 126 CCP 
genes from the Gene Expression Omnibus database and 
tested their performance with RNA extracted from 
96 commercially available FFPE prostate tumour sections 
(Asterand, Detroit, MI, USA) obtained from anonymous 
patients. No demographic or clinical data were available for 
these specimens. Expression of diﬀ erent CCP genes was 
shown to be highly correlated,29 presumably indicating the 
fraction of actively dividing cells within the sampled tissue. 
Therefore, we selected genes for inclusion in the signature 
on the basis of their correlation with the mean expression 
of the entire set of CCP genes (webappendix pp 1–4). The 
ﬁ nal signature consisted of 31 CCP genes (FOXM1, CDC20, 
CDKN3, CDC2, KIF11, KIAA0101, NUSAP1, CENPF, 
ASPM, BUB1B, RRM2, DLGAP5, BIRC5, KIF20A, PLK1, 
TOP2A, TK1, PBK, ASF1B, C18orf24, RAD54L, PTTG1, 
CDCA3, MCM10, PRC1, DTL, CEP55, RAD51, CENPM, 
CDCA8, and ORC6L). These highly correlated genes were 
used to provide a robust and highly reproducible 
measurement of cell proliferation and were not intended 
to capture information related to other factors 
(eg, invasive potential).
Radical prostatectomy cohort
Men who had undergone radical prostatectomy for 
prostate cancer from 1985–95 were identiﬁ ed through 
the tumour registry at the Scott and White Clinic, 
Temple, TX, USA. The list was submitted to the pathology 
department, and patients were matched to the accession 
numbers of the specimens obtained during radical 
prostatectomy. We attempted to identify tissue blocks for 
every patient who was selected for inclusion in the 
cohort. Tissue blocks were retrieved, and sections were 
cut for ten slides from each block for analysis. The 
middle slide was stained with haematoxylin and eosin to 
conﬁ rm the presence of cancer. The specimens were 
inked, and pathological ﬁ ndings were recorded as 
positive for bladder neck or urethral margin, invasion 
into the capsule, extension through the capsule, positive 
margins, and the involvement of the seminal vesicles. 
Biochemical recurrence was deﬁ ned as a PSA 
concentration greater than 0·3 ng/mL based on the 
management policy used in the 1990s, and was not 
changed for this analysis. Death from disease was 
deﬁ ned as death with disease progression after 
biochemical recurrence of prostate cancer. We selected 
patients who had not been treated with neoadjuvant 
drugs and for whom clinical data and tumour tissue 
were available for inclusion in this study to create a 
retrospective cohort. Patients who had been treated with 
neoadjuvant drugs were excluded because these would 
aﬀ ect the interpretation of the Gleason and CCP scores. 
Institutional review board approval was obtained from 
the Scott and White Clinic.
Transurethral resection of prostate (TURP) cohort
For the population-based retrospective watchful-waiting 
cohort, potential cases of prostate cancer were identiﬁ ed 
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Figure 1: Flow chart of cohort with radical prostatectomy
804 consecutive patients with radical
prostatectomy
29 no clinical data
333 no available tissue
32 excluded because of treatment 
       with neoadjuvant therapies
44 excluded because of poor-quality
cell-cycle-progression scores
775 with clinical data
442 with available tumour tissue
410 eligible for analysis
366 analysed for gene expression data
See Online for webappendix
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from six cancer registries in Great Britain. Within each 
region, cases from collaborating hospitals were reviewed, 
and full details of these cases have been reported.31 Men 
were included in this study if they had clinically localised 
prostate cancer, which was diagnosed by use of TURP 
between 1990 and 1996 (inclusively), were younger than 
76 years at the time of diagnosis, and had a baseline PSA 
measurement. Patients treated with radical prostatectomy 
or radiation therapy, or who died or showed evidence of 
metastatic disease31 within 6 months of diagnosis were 
excluded. Men who had hormone therapy before 
diagnostic biopsy were also excluded because of the 
eﬀ ects of hormone treatment on interpretation of the 
Gleason score.
Original histological specimens from the diagnostic 
procedure were requested, collected, and centrally 
reviewed by a panel of expert urological pathologists to 
conﬁ rm the TURP diagnosis and, when necessary, to 
reassign Gleason scores for all the prostate cancers by 
use of a contemporary interpretation16 of the Gleason 
scoring system. Follow-up was through the cancer 
registries and the last review took place in December, 2006. 
Deaths were divided into two categories, those from 
prostate cancer and those from other causes, according 
to WHO’s standardised criteria.32
National ethics approval was obtained from the 
Northern Multicentre Research Ethics Committee, 
followed by local ethics committee approval at each of 
the collaborating hospitals for the TURP cohort 
(webappendix p 6).
Gene expression
Depending on tumour volume, ﬁ ve to 12 consecutive 
5 μm (TURP) or 10 μm (prostatectomy) FFPE tumour 
sections were used to isolate tumour-derived RNA. The 
tumour region was dissected from the slide with a razor 
blade, according to the pathologist’s instructions, into a 
microfuge tube. The paraﬃ  n was removed by use of 
xylene and the tumour sample was washed with ethanol. 
Samples were then digested overnight with proteinase K 
digestion at 55°C.
Total RNA was extracted with RNeasy FFPE or 
miRNeasy (Qiagen, Valencia, CA USA) as described by 
the manufacturer (with the exception of the extended 
proteinase K digestion). The miRNeasy kit became 
available after we had isolated RNA from about a third of 
the cohort of patients who had undergone radical 
prostatectomy. We switched from RNeasy FFPE to 
miRNeasy because the new kit consistently generated 
Figure 2: Analysis of cell cycle progression (CCP) score in cohort with 
radical prostatectomy
(A) Distribution of the CCP scores for 366 patients. Red tick marks on the x-axis 
indicate the median score (0·16) and IQR (0·30 to 0·64). Q=quarter. (B) Analysis of 
CCP scores in diﬀ erent clinical subgroups. Data are n/N (%), unless otherwise 
indicated. The size of the each box is proportional to the number of recurrences 
within that subgroup. The horizontal lines indicate the 95% CI for each hazard 
ratio. (C) Kaplan-Meier analysis of recurrence versus time. Each group corresponds 
to a doubling in CCP expression. *10-year estimated biochemical recurrence rates.
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better RNA yields. No diﬀ erence was noted between the 
kits in terms of the data for gene expression.
Total RNA was treated with DNase I (Sigma-Aldrich, 
St Louis, MO, USA) before cDNA synthesis. We used the 
High-capacity cDNA Archive Kit (Applied Biosystems, 
Foster City, CA USA) to convert total RNA into single 
strand cDNA as described by the manufacturer. Ideally, at 
least 200 ng of RNA was required for the reverse 
transcription, but use of smaller input amounts was also 
successful. The quality of the RNA was not ideal because 
of sample age. In the development of this assay, careful 
attention was given to obtaining a reliable score for the 
tumour samples. RNA quality was assessed on the basis 
of the ampliﬁ cation of the CCP and housekeeper genes. 
To generate a CCP score, essentially all the housekeeping 
genes and at least 21 CCP genes had to be ampliﬁ ed. We 
attempted to generate a CCP score from every sample. 
For some of the samples, some genes did not amplify, 
indicating that the RNA quality was too poor to obtain 
a score. However, most samples (90% of radical 
prostatectomy cohort and 85% of TURP cohort) could be 
used to generate CCP scores, and therefore, had RNA of 
adequate quality.
Before measurement of gene expression, the cDNA 
was preampliﬁ ed in a pooled reaction containing 
TaqMan assays (Applied Biosystems). Preampliﬁ cation 
reaction conditions were 14 cycles at 95°C for 15 s and 
60°C for 4 min. The ﬁ rst cycle also included 10 min 
incubation at 95°C. The ampliﬁ cation reaction was 
diluted 1:20 with the 1×Tris-EDTA buﬀ er before it was 
loaded on TaqMan Low Density arrays (Applied 
Biosystems) to assess the ampliﬁ ed genes. Expression 
data were recorded as a threshold cycle value, the PCR 
cycle at which the ﬂ uorescence intensity exceeded a 
predeﬁ ned threshold. A total of 31 predeﬁ ned CCP 
genes and 15 housekeeper genes were ampliﬁ ed on one 
TaqMan Low Density array.
CCP score
The CCP score for each individual was calculated. The 
values of each of three replicates of each of the 31 CCP 
genes were normalised by subtraction of the average of 
up to 15 non-failed housekeeper genes for that replicate 
(centred with a predeﬁ ned value) to give ΔC*T. Then, a 
predeﬁ ned baseline value was subtracted from ΔC*T to 
create ΔΔC*T. This quantity was then converted to a 
value that was proportional to the copy number, 
calculated as 2–ΔΔC
*
T.
For missing ΔΔC*T values, due to low expression, 2–ΔΔC
*
T 
was set as equal to 0. For each CCP gene, the mean 2–ΔΔC
*
T 
of the qualifying replicates—ie, those with expression of 
at least 13 housekeeper genes, was then averaged over 
the qualifying CCP genes. This is the normalised average 
of 2–ΔΔC
*
T and was converted back to create the CCP score 
by taking a base 2 logarithm. A CCP gene was judged as 
having failed if more than one replicate did not qualify, 
or if two replicates qualiﬁ ed and one of them had 2–ΔΔC
*
T 
equal to 0, or if the standard deviation between the three 
Univariate analysis Multivariate analysis (n=353) Final model
n (%) N Hazard ratio 
(95% CI)
χ2 (1 df) p value Hazard ratio 
(95% CI)
χ2 (1 df) p value N Hazard ratio 
(95% CI)
χ2 (1 df) p value
CCP score* ·· 366 1·89 (1·54–2·31) 33·96 5·6×10–9 1·77 (1·40–2·22) 21·13 4·3×10–6 353 1·74 (1·39–2·17) 21·65 3·3×10–6
log(1+baseline PSA) ·· 395 3·07 (2·38–3·97) 71·12 3·4×10–17 1·98 (1·47–2·65) 20·65 5·5×10–6 353 2·24 (1·71–2·93) 33·47 7·2×10–9
Gleason score (radical prostatectomy)
<7 ·· 269 1·00 ·· ·· 1·00 ·· ·· 230 1·00 ·· ··
7 ·· 123 2·81 (2·01–3·94) 54·56† 1·5×10–13 1·11 (0·71–1·71) 2·58† 0·11 108 1·35 (0·92–2·00) 7·57† 5·9×10–3
>7 ·· 18 6·32 (3·65–10·93) ·· ·· 2·10 (1·05–4·18) ·· ·· 15 2·69 (1·43–5·08) ·· ··
Pathological T stage ·· 410 1·66 (1·48–1·88) 67·70 2·2×10–16 1·15 (0·87–1·51) 1·09 0·30 353 1·32 (1·12–1·56) 10·30 1·3×10–3
Pathological grade 410 2·42 (1·89–3·11) 48·45 3·4×10–12 1·24 (0·89–1·73) 1·65 0·20 ·· ·· ·· ··
Positive surgical margins 96 (23%) 410 3·44 (2·48–4·76) 49·53 2·0×10–12 1·88 (0·94–3·75) 3·55 0·06 353 1·89 (1·23–2·91) 8·61 3·3×10–3
Extracapsular extension 121 (30%) 410 3·34 (2·43–4·61) 51·53 7·0×10–13 1·29 (0·58–2·84) 0·38 0·54 ·· ·· ·· ··
Bladder involvement 19 (5%) 410 3·02 (1·67–5·46) 10·03 1·5×10–3 2·11 (1·09–4·08) 4·17 0·041 ·· ·· ·· ··
Seminal vesicle 
involvement
44 (11%) 410 4·53 (3·05–6·71) 42·42 7·3×10–11 1·43 (0·67–3·07) 0·83 0·36 ·· ·· ·· ··
Positive lymph node 13 (3%) 410 4·14 (2·10–8·18) 11·53 6·9×10–4 1·54 (0·70–3·38) 1·09 0·30 ·· ·· ·· ··
Age at surgery ·· 410 1·02 (0·99–1·05) 2·47 0·12 1·01 (0·98–1·05) 0·76 0·38 ·· ·· ·· ··
Diagnostic variables
Gleason score (biopsy) ·· 410 2·42 (1·84–3·17) 31·78 1·7×10–8 ·· ·· ·· ·· ·· ·· ··
Clinical stage ·· 410 1·48 (1·17–1·87) 11·51 6·9×10–4 ·· ·· ·· ·· ·· ·· ··
Clinical grade ·· 410 2·21 (1·76–2·77) 45·99 1·2×10–11 ·· ·· ·· ·· ·· ·· ··
Data are number (%), unless otherwise indicated. df=degrees of freedom. PSA=prostate-speciﬁ c antigen. *Hazard ratio for 1-unit increase in cell cycle progression (CCP) score. †χ2 values were 54·93, 4·15, 
and 8·41 in the univariate analysis, multivariate analysis, and ﬁ nal model, respectively, when Gleason scores were assessed as a three-group categorical variable with 2 degrees of freedom. 
Table 1: Summary of statistical analysis of prostatectomy cohort, by biochemical recurrence
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replicate ΔΔC*T values exceeded 0·5. CCP scores with the 
number of failing CCP genes greater than nine of 31, or a 
high SD between scores calculated from the three 
replicates, were rejected and excluded from the analysis. 
The interassay variability has been established in our 
laboratory and the SD of the CCP score for experimental 
replicates is 0·1.
Statistical analysis
Survival analysis was done with Cox proportional hazards 
models. The primary endpoint for the cohort of patients 
who had radical prostatectomy was time to biochemical 
recurrence. Follow-up times started on the date of 
surgery, and observations were censored on the date of 
last follow-up. The secondary endpoint was death after 
progression. Observations were censored on the date of 
last follow-up or death without evidence of disease or 
death with stable disease. The clinical variables recorded 
for the prostatectomy cohort were diagnostic Gleason 
score, most recent prebiopsy PSA concentration, clinical 
stage, clinical grade, primary treatment (no preoperative 
or postoperative hormones, orchiectomy, or adjuvant 
radiation), age at surgery, pathological tumour stage, 
pathological grade, pathological Gleason score, and 
invasion features.
The primary endpoint for the TURP cohort was time 
to death from prostate cancer. Biochemical progression 
was not an appropriate outcome for this cohort, since 
baseline PSA concentrations remain elevated and some 
patients will have chosen to start hormones or have 
radical treatment without evidence of increasing PSA 
concentration. Observations were censored on the date 
of last follow-up, or death from other causes. Follow-up 
times started 6 months after the date of diagnosis. The 
variables recorded for the TURP cohort were centrally 
reviewed Gleason grade and score, baseline PSA value, 
clinical stage, extent of disease (proportion of TURP 
chips with disease), age at diagnosis, and initial treatment 
(no initial treatment or early hormone management). 
Ki67 (percentage of cells that were positive) was 
measured by an immuno histochemical assay.33 Baseline 
PSA concentration was deﬁ ned as the last PSA 
concentration within 6 months of diagnosis (including 
prediagnostic concentrations), but before initiation of 
hormone therapy and at least 3 weeks after any biopsy. 
The analysis set and a complete analysis plan were 
agreed, and all CCP scores were assigned, before the 
clinical and outcome data were unmasked.
In both cohorts, PSA concentration was modelled as 
the natural logarithm of 1+PSA (ng/mL). Values greater 
than 100 were excluded as likely to be metastatic disease. 
As indicated above, for the prostatectomy cohort, only a 
single pathological Gleason score was recorded at 
diagnosis; for the TURP cohort, 3+4 and 4+3 were 
shown to have nearly identical prognosis.13,31 Therefore, 
a total Gleason score of 7 was analysed as one group. 
For simplicity, Gleason scores were grouped into less 
than 7, 7, and greater than 7 (radical prostatectomy 
cohort: less than 7 [56% with score 6], greater than 7 
[75% with score 8, 19% with score 9]; TURP cohort: less 
than 7 [88% with score 6 (all 3+3)], 7 [34% with score 
4+3], and greater than 7 [51% with score 8, 46% with 
score 9]). Models were ﬁ tted with Gleason score as a 
three-group categorical variable. All p values were two-
sided and 95% CIs and p values were based on χ² 
statistics with 1 degree of freedom obtained from partial 
likelihood models.
The main assessment was a univariate analysis of the 
association between outcome and CCP score. A further 
predeﬁ ned assessment of the added prognostic 
information after adjustment for the baseline variables 
was also undertaken. This later eﬀ ect was measured by 
use of the decrease in the likelihood ratio χ² when the CCP 
score was omitted from a model containing it and the 
other relevant baseline clinicopathological variables. In 
construction of the best prognostic model, the goal was to 
capture most of the prognostic information from the CCP 
score and the clinical covariates in a simple linear model 
without overﬁ tting the data. A multivariate proportional 
(Cox) hazards model was used to achieve this goal and to 
create a combined score based on the major clinical 
variable and the CCP score. The CCP score was evaluated 
Figure 3: 10-year predicted risk of recurrence for diﬀ erent combined risk scores in cohort with radical 
prostatectomy (A), and distribution of the combined risk scores for diﬀ erent subgroups based on Gleason 
scores (B)
The probability of recurrence was estimated from a Cox proportional hazard model by use of the combined risk score.
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as a linear and a quadratic term, and tested for interactions 
with individual covariates. We used a forward stepwise 
regression in which a new variable was added only if it 
had a p value of less than 0·02 for the prostatectomy study 
and 0·05 for the TURP study (since fewer variables were 
tested). Next, we evaluated the prognostic utility of the 
CCP signature after accounting for clinical variables. We 
included all available postsurgical clinical variables and 
any presurgical variables that did not have a postsurgical 
equivalent in our multivariate analysis. Statistical analyses 
were done with STATA/IC (version 10.1), S+ (version 8.1.1 
for Linux) or R (version 2.9.0).
Role of the funding source
The study sponsor (Queen Mary University of London) 
and funders Cancer Research UK, Orchid Appeal, US 
National Institutes of Health, and Koch Foundation had 
no role in the design of the study, collection, analysis, or 
interpretation of the data, or in writing the report, or the 
decision to publish the results. Myriad Genetics has 
provided funding support to Queen Mary University of 
London to facilitate preparation of tumour blocks. The 
cell cycle expression proﬁ les were assayed blind to all 
other data by Myriad Genetics. Analysis of the TURP 
cohort was undertaken at Queen Mary University of 
London under the direction of JC, following a predeﬁ ned 
statistical analysis plan. Interpretation of the data and 
the ﬁ nal content of this report were approved by all 
authors. The corresponding author had full access to the 
data (as did SS, JER, and DM), and takes full responsibility 
in submitting the report for publication.
Results
For the radical prostatectomy cohort, patients’ 
characteristics and treatment outcomes have been 
reported previously.33 Figure 1 summarises the selection 
of 410 patients for this study who underwent radical 
prostatectomy. The median follow-up time for the 
selected patients was 9·4 years  (6·8–10·9). Median age 
of patients was 68 years (63–71). The clinical T stages 
were T1 (135 [33%] of 410) and T2 (275 [67%]). The 
pathological T stages were T1 (one [<1%]), T2 (271 
[66%]), and T3 (138 [34%]). The median preoperative 
PSA concentration was 6·9 ng/mL (4·6–10·9), and 281 
(71%) of 397 patients had PSA concentrations less than 
10 ng/mL. 148 (36%) of 410 patients had biochemical 
recurrence by 10 years after surgery.  After exclusion of 
poor-quality CCP scores, 366 (89%) samples were 
judged valid for statistical analysis. The clinical 
characteristics of the excluded patients were similar to 
those that were included in the analysis 
(webappendix pp 4–5). Figure 2A shows the distribution 
of the CCP scores. A unit change in the score 
corresponds to a doubling in expression level.
The univariate analysis showed that in the patients who 
had undergone radical prostatectomy, a high CCP score 
was predictive of biochemical recurrence (table 1). 
Addition of a quadratic term for CCP score was not 
signiﬁ cant (p=0·63), indicating that a simple linear 
model would capture most of the prognostic information 
from the signature. The increase in hazard ratio for a 
1-unit change in CCP score was 1·89 (95% CI 1·54–2·31). 
The CCP score was only weakly correlated with other 
variables, the highest correlation was with the Gleason 
score and PSA (Pearson’s  values, 0·22 and 0·21 
respectively). The CCP score was also higher in patients 
with positive lymph nodes (p=0·003), but only 13 patients 
had positive nodes. CCP was prognostic for diﬀ erent 
Gleason scores, PSA concentrations, and pathological 
stages (ﬁ gure 2B). However, patients with higher clinical 
Figure 4: Flow chart of cohort with transurethral resection of prostate (TURP)
PSA=prostate-speciﬁ c antigen.
2333 eligible patients
675 excluded
203 not requested
472 excluded after review
283 unknown or missing
histology slides
43 incorrect pathology
specimen
135 histologically ungradeable
Gleason score
6 no tissue in block
5 histologically ungradeable
Gleason score
1658 reviewed histology and
assigned Gleason score
911 diagnosed by use of TURP
482 not included in this study
61 excluded because of poor-quality 
      cell-cycle progression scores
31 ineligible for study
 9 PSA >100 ng/mL
 7 previous hormone therapy
 6 missing baseline PSA
 4 previous cancer
 4 metastases within 6 months
 1 biopsy not between 1990–96
429 unselected samples identiﬁed
for analysis
398 available for analysis
747 diagnosed by use of needle
biopsy
337 eligible in ﬁnal analysis
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risk (ie, Gleason score >6 and PSA concentrations 
>10 ng/mL) tended to have a reduced CCP hazard 
ratio (HR). However, the test for heterogeneity was not 
signiﬁ cant. Figure 2C shows that the proportion of 
patients who developed biochemical recurrence at 
diﬀ erent follow-up times increased as the CCP score 
increased. 12 (3%) of 366 patients who had undergone 
radical prostatectomy died with disease progression. The 
CCP score was predictive for death after disease 
progression (HR 2·99, 95% CI 1·69–5·28; p=0·0007).
In the full multivariate analysis of the prostatectomy 
cohort, CCP and PSA concentration were the most 
signiﬁ cant predictors of biochemical recurrence, and 
provided more prognostic information than did any 
other variable (table 1). From comparison of χ² values, 
CCP and PSA were the only variables that retained a 
substantial portion of their univariate information. The 
best multivariate model was developed by forward 
stepwise regression and is given by combined risk score
Figure 3A shows how the risk of biochemical recurrence 
in the ﬁ nal 10 years increased as a function of the 
combined risk score, and given the central prognostic 
role of the Gleason score, ﬁ gure 3B shows the distribution 
of combined risk score in diﬀ erent Gleason score 
categories.
For the TURP cohort, the selection of patients is 
summarised in ﬁ gure 4. We report the results obtained 
with a randomly selected subset of 337 men diagnosed by 
use of TURP for which we were able to compute the CCP 
score (ﬁ gure 4). Characteristics of the patients excluded 
were much the same as those included in the analyses 
(webappendix p 5). Median follow up was 9·8 years 
(IQR 5·4–11·8). Within 10 years of diagnosis, 171 (51%) of 
337 men had died, 68 (20%) from prostate cancer and 
103 (31%) from other causes.
Figure 5A shows the distribution of the CCP score 
among the 337 patients in the TURP cohort. By 
comparison with the Gleason score, PSA, cancer extent, 
and Ki67, the CCP score provided the most prognostic 
information in the univariate analysis, with the χ² being 
slightly greater than that for the Gleason score (table 2), 
and substantially larger than for all other variables. 
Compared with the prostatectomy cohort, the CCP score 
Figure 5: Analysis of cell cycle progression (CCP) score in cohort with 
transurethral resection of prostate (TURP)
(A) Distribution of the CCP scores (n=337). Red tick marks on the x-axis indicate 
the median score (0·67) and IQR (0·15–1·35). (B) Analysis of CCP scores in 
diﬀ erent clinical subgroups. Data are n/N (%), unless otherwise indicated. The 
size of each box is proportional to the number of deaths within that subgroup. 
The horizontal lines indicate the 95% CI for each hazard ratio. (C) Kaplan-Meier 
estimates of prostate cancer death versus time. Each group corresponds to a 
doubling in CCP expression. *10-year estimated prostate cancer death rates for 
each group.
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correlated more with Gleason score (Pearson’s =0·61), 
log(1+ PSA) (=0·27), Ki67 (=0·50), and extent of disease 
(=0·51). The prognostic value of the CCP score was 
similar in diﬀ erent Gleason categories and when 
stratiﬁ ed by PSA, extent of disease, and Ki67 (ﬁ gure 5B). 
Addition of a quadratic term for CCP score was non-
signiﬁ cant (p=0·36). Figure 5C shows a Kaplan-Meier 
plot of the proportion of patients dying of prostate cancer 
at diﬀ erent follow-up times grouped by integer values of 
the CCP score.
In the full multivariate analysis, after adjustment for 
PSA concentration, Gleason score, Ki67 expression, and 
extent of disease, the CCP score was dominant (table 2), 
providing more information than did any other variable. 
None of the variables showed a signiﬁ cant interaction 
with the CCP score, and the HR for the CCP score was 
only slightly attenuated when other factors were added to 
the model (table 2). As in the postsurgical cohort, PSA 
concentration was highly predictive of outcome (table 2) 
and it also retained much of its univariate information. 
Hormone treatment was signiﬁ cant in a univariate model 
(HR 3·81, 95% CI 2·40–6·05), but did not add signiﬁ cant 
predictive information in the multivariate model (1·12, 
0·68–1·84), presumably because the decision to use this 
treatment was based on the known prognostic factors. 
Addition of a quadratic term for CCP was also not 
signiﬁ cant in the multivariate model (p=0·13).
In the forward stepwise regression model, with the 
variables CCP, PSA concentration, and Gleason score, 
the best predictor was the combined risk score 
calculated as
0·95 CCP + 0·61 log (1+PSA) +  {0·90 (Gleason score 7) 
+  1·00 (Gleason score>7)}
Figure 6A shows the predicted 10-year death rate from 
prostate cancer increases as a function of the 
combined score; ﬁ gure 6B shows the distribution of the 
combined score in diﬀ erent Gleason score categories. In 
terms of selection of patients for conservative 
management, evaluation of the combined score is 
informative for identiﬁ cation of disease with a low fatality 
risk. For men with a tumour that was Gleason score 6 or 
less, use of the combined score identiﬁ ed 28 (16%) of 
172 patients with a 10-year risk of death from prostate 
cancer that was less than 2%, and 102 (59%) of 172 with a 
risk less than 5%, but also identiﬁ ed 25 (15%) with a risk 
greater than 10%, indicating that not all Gleason 
score 6 or less tumours are low risk. For Gleason score 7 
Death from prostate cancer
Univariate analysis Multivariate analysis (n=290) Final model
N Hazard ratio (95% CI) χ2 (1 df) p value Hazard ratio (95% CI) χ2 (1 df) p value N Hazard ratio (95% CI) χ2 (1 df) p value
CCP score* 337 2·92 (2·38 to 3·57) 92·7 6·1×10–22 2·56 (1·85 to 3·53) 32·3 1·3×10–8 337 2·57 (1·93 to 3·43) 42·2 8·2×10–11
Gleason score
<7 172 1·00 ·· ·· 1·00 ·· ·· 172 1·00 ·· ··
7 73 5·20 (2·40 to 11·29) 80·0† 3·7×10–19 2·45 (0·95 to 6·30) 4·2† 0·04 73 2·45 (1·09 to 5·48) 5·4† 0·02
>7 92 13·67 (6·90 to 27·11) ·· ·· 2·91 (1·12 to 7·55) ·· ·· 92 2·72 (1·22 to 6·08) ·· ··
log(1+PSA) (ng/mL) 337 2·30 (1·83 to 2·88) 57·5 3·4×10–14 1·87 (1·44 to 2·44) 24·9 6·0×10–7 337 1·84 (1·46 to 2·32) 29·3 6·2×10–8
log(1+[10×Ki67]) (%) 295 1·77 (1·43 to 2·20) 32·2 1·4×10–8 0·98 (0·80 to 1·21) 0·03 0·86 ·· ·· ·· ··
Cancer extent (%)‡ 330 1·26 (1·19 to 1·34) 56·6 5·3×10–14 1·01 (0·93 to 1·10) 0·11 0·74 ·· ·· ·· ··
df=degrees of freedom. CCP=cell cycle progression. PSA=prostate-speciﬁ c antigen. *Hazard ratio for a unit increase in CCP score. †χ2 values were 81·3, 5·4, and 7·1 in the univariate analysis, multivariate analysis, 
and ﬁ nal model, respectively, when Gleason score was assessed as a three-group categorical variable with 2 df (when increased to ﬁ ve groups, χ2 values were 9·4, 5·4, and 7·2, respectively). ‡Hazard ratio for 10% 
increase in cancer extent. 
Table 2: Summary of statistical analysis of transurethral resection of the prostate cohort
Figure 6: 10-year predicted risk of prostate cancer death for diﬀ erent combined risk scores in cohort with 
transurethral resection of prostate (A), and distribution of the combined risk scores for diﬀ erent subgroups 
based on Gleason scores (B)
The probability of prostate cancer death was estimated from a Cox proportional hazard model by use of the 
combined risk score.
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(either 3+4 or 4+3), the corresponding data were none of 
73 patients, eight (11%), and 59 (81%), respectively. In the 
whole cohort, the numbers and percentages were 28 (8%) 
of 337, 111 (33%), and 173 (51%), respectively.
When we assessed deaths from other causes, the only 
signiﬁ cant factor was age. Neither the CCP score nor 
other major prognostic factors for prostate cancer death 
were signiﬁ cant causes, indicating that confounding by 
other deaths cannot explain these ﬁ ndings.
Discussion
The CCP score was predictive of outcome in both cohorts 
and provided substantially more prognostic information 
than did clinical variables alone. Expression of CCP genes 
is higher in actively growing cells, and presumably by 
measuring the expression of CCP genes, we are indirectly 
measuring the growth rate and inherent aggressiveness 
of the tumour, which ultimately aﬀ ects outcome. Since 
we are assessing fundamental tumour biology, we predict 
that the prognostic usefulness of the CCP score is highly 
robust. Three of the genes in our signature—TOP2A, 
RRM2, and BIRC5—have been previously associated with 
prostate cancer outcome,14,15 but we believe the use of a 
larger panel will ensure robustness of the score. Notably, 
many CCP genes are putative targets of cytotoxic or 
radiation therapies: RRM (pemetrexed and gemcitabine), 
TOP 2A (anthracyclines), KIF11 and KIF20A (taxanes), 
TK1 (ﬂ uorouracil), and RAD51 and RAD54L (radiation, 
alkylating drugs, and novel targeted drugs), and therefore 
CCP may be useful in predicting response to treatment.
Both cohorts have their strengths and weaknesses. Both 
had long-term follow-up with a median approaching 
10 years. The cohort of patients who had undergone 
radical prostatectomy were mainly screen detected, and 
had lower baseline Gleason scores and PSA concentrations, 
but a very low death rate from prostate cancer. The TURP 
cohort had more aggressive disease, which meant that 
prostate cancer mortality could be reliably modelled, but 
was all based on symptomatic patients and TURP 
samples, which is unusual in contemporary practice. 
Despite the very diﬀ erent clinical settings in which we 
have tested the CCP score, the resultant predictive models 
were quite similar. In both settings, CCP score and PSA 
concentration were the dominant variables, whereas other 
clinical variables (including Gleason score) did not retain 
most of their univariate prognostic usefulness. These 
data suggest that measurements of CCP score and PSA 
concentration represent independent aspects of disease 
aggressiveness and are both required for an accurate 
prediction of outcome. By contrast Ki67, which is coded 
for by a CCP gene and by itself can be predictive of 
outcome in this dataset,34 was eliminated from models 
that included CCP score. Immunohistochemical 
assessment of Ki67 is dominated in the predictive models 
probably because measurement of the CCP score through 
RNA concentrations is more quantitative and better 
represents the underlying biology.
The evidence presented here indicates that the CCP 
score adds signiﬁ cantly to the predictive power of the 
clinical variables typically used to predict disease 
outcome after surgery and at the time of disease 
diagnosis. Although potentially useful in both of these 
settings, the most pressing clinical need is to accurately 
separate indolent disease in men with newly diagnosed 
cancer, which is unlikely to be fatal, from the more 
aggressive cancers in need of radical treatment. 
Currently, Gleason score and baseline PSA concentration 
are the strongest predictors, and extent of disease and 
Ki67 add only a small additional discrimination.34 Clinical 
stage, which was only available for some of the TURP 
cohort, was only weakly predictive of outcome in previous 
analyses.31 Results from the univariate analysis of the 
TURP cohort have shown that the CCP score was a 
stronger predictor of death from prostate cancer than 
Panel: Research in context
Systematic review
We searched Pubmed through the National Center for 
Biotechnology Information search engine with key terms 
“prostate cancer”, “prognostic”, and “RNA expression”. JSL 
and SS reviewed these for quality and relevance. The key 
publications are described and referenced in our introduction. 
The results of previous studies were equivocal. Generally, 
authors did not show, or did not convincingly show, that their 
signatures added information beyond clinical variables. Also, 
the ﬁ ndings of most studies were not shown to be robust in 
terms of patient composition or clinical setting.
To develop the cell cycle progression (CCP) score, we 
downloaded and analysed every large publicly available 
expression dataset that was associated with cancer outcome 
(Gene Expression Omnibus database). As a result, we 
concluded that CCP genes were the key components in every 
validated prognostic signature, and this conclusion was in 
accord with Mosley and colleagues.29
Interpretation
Although the appropriate management of early prostate 
cancer is widely acknowledged to be a major clinical issue, 
none of the previously deﬁ ned prognostic signatures have 
had a major eﬀ ect on clinical care. Results of previous studies 
have indicated a need to improve stratiﬁ cation of these 
patients to guide the need for radical treatment. In this study, 
we addressed all these issues, and the results indicate that the 
CCP score can be helpful in assessing prognosis in a range of 
settings, especially for patients with a good prognosis such as 
Gleason score 6. The CCP score is a robust measure of the 
proliferative activity in the tumour and might be useful in 
ascertaining which prostate cancers can be safely managed 
with a conservative strategy. Further validation studies are 
needed, especially for screen-detected cancers that are 
diagnosed by use of needle biopsy when conservative 
management is an option.
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were any of the other variables, and multivariate analysis 
indicated that this score added a substantial amount of 
prognostic information not captured by any other 
measure. This result is supported by an HR of 1·74 in 
the prostatectomy cohort and 2·57 in the TURP cohort 
in the multivariate model for a 1-unit increase in the 
CCP score. When the CCP score was adjusted for clinical 
variables, the HRs were 1·68 and 3·06, respectively, for a 
change from the 25th to 75th percentiles of the CCP 
score distributions in each cohort. Although the area 
under the receiver operating characteristic curve (AUC) 
does not account for time-to-event information or 
censoring, it has become a common way to compare 
predictive scores for an event. For an event in the ﬁ rst 
5 years, the AUC in the prostatectomy cohort for 
biochemical recurrence was 0·825 for the clinical score, 
and 0·842 for the combined score (including the CCP 
score). For the TURP cohort, the values were 0·806 
and 0·878 for death from prostate cancer, respectively. 
Additionally, the added value of the CCP score to clinical 
variables can be noted by comparison of the outcomes of 
patients in the lowest quartile versus highest quartile of 
the clinical score versus the combined score. Comparison 
of the 10-year event proportions in the highest quartile 
showed that the Kaplan-Meier estimates were 84·3% 
(clinical score) versus 83·6% (combined score) for the 
cohort of patients who had under gone radical 
prostatectomy (biochemical recurrence), and 62·6% 
versus 67·4%, respectively, for the TURP cohort (death 
from prostate cancer). For the lowest quartile, the 
estimates were 6·9% versus 4·6%, respectively, for the 
prostatectomy cohort, and 2·7% versus 1·3%, 
respectively, for the TURP cohort. Thus, the combined 
score seems to be particularly helpful for the patients in 
the lowest quartile, in which the clinical need for better 
prediction is greatest. Therefore, addition of the CCP 
score to clinical variables allows more accurate prediction 
of which men can be safely managed by watchful waiting, 
and, of equal importance, which men with apparently 
low-risk disease actually are at high risk of death from 
prostate cancer and might beneﬁ t from radical treatment. 
For example, 8% of the entire cohort and 15% of men 
with a Gleason score of 6 or less could be identiﬁ ed with 
a 10-year death rate from prostate cancer of less than 2%, 
and 17% of those with a Gleason score of 6 or less still 
had a 10-year death rate from prostate cancer of more 
than 10%.
CCP genes have been shown to be prognostic in breast 
cancer.29 They have also proven to be prognostic in lung 
and brain cancers.35,36 The results of these previous 
studies led us to assess whether CCP genes would be 
useful in prostate cancer. A major strength of our study 
is that we tested one predeﬁ ned score based on CCP 
genes, as opposed to assessing several genes separately. 
As a result, the interpretation of this study is not 
complicated by the extensive multiple testing inherent 
in more comprehensive discovery strategies, and, 
therefore, we can be highly conﬁ dent about the main 
conclusions of this report. We do not claim, however, 
that the CCP score contains every gene that might be 
prognostic in prostate cancer, and additional studies 
might uncover biomarkers that greatly improve the 
overall performance of our predictive models. The CCP 
score is a robust predictor of prostate cancer outcome 
and its measurement is an important step in 
personalising treatment for prostate cancer (panel). 
However, this score needs to be further validated in 
contemporaneous cohorts diagnosed by use of needle 
biopsy. Assessment of the value of the CCP score in 
clinical trials of adjuvant radiation, androgen deprivation, 
and other systemic treatments is warranted to establish 
whether this signature can help in the decisions about 
treatments in that setting too.
Contributors
All authors approved the ﬁ nal report and contributed to the study. JC, 
SS, and GPS participated in the experimental design, writing the 
report, and data analysis. JSL, AG, and GF were involved in the study 
plan, design, and data interpretation. JC, DM, and JER participated in 
the statistical analysis. SW, JP, AY, and DDF were involved in the 
generation of CCP data and development of the CCP score. JDW 
participated in sample preparation and assay. For the TURP cohort 
study, JC and GF contributed to the experimental design, writing the 
report, and data analysis; DMB and CSF participated in the pathology 
review and interpretation; HM was involved in coordinating cancer 
registry clinical data; ES participated in specimen preparation; PS and 
HM were involved in the study plan and design. For the prostatectomy 
cohort study, GPS and ARB were involved in the experimental design, 
writing the report, and data analysis; VOS participated in the 
pathology review and interpretation; and JER, AG, and DDF 
contributed to the statistical analysis.
Conﬂ icts of interest
JSL, AG, SS, SW, AY, DDF, JP, JER, and JDW are employees of Myriad 
Genetics. GPS has received a travel grant from Myriad Genetics. ARB 
was a previous consultant for Myriad Genetics. The other authors 
declared that they have no conﬂ icts of interest.
Acknowledgments
We gratefully recognise the patients who participated in this study and 
the support from Cancer Research UK, Queen Mary University of 
London, the Orchid Appeal, National Institutes of Health 
(SPORE CA92629), and the Koch Foundation and Myriad Genetics. 
We also thank investigators and staﬀ  in the cancer registries and 
participating hospitals for their support (webappendix p 6).
References
1 Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. 
CA Cancer J Clin 2009; 59: 225–49.
2 Evans HS, Moller H. Recent trends in prostate cancer incidence 
and mortality in southeast England. Eur Urol 2003; 43: 337–41.
3 Schroder FH, Hugosson J, Roobol MJ, et al. Screening and 
prostate-cancer mortality in a randomized European study. 
N Engl J Med 2009; 360: 1320–28.
4 Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate 
at autopsy in seven areas. The International Agency for Research 
on Cancer, Lyon, France. Int J Cancer 1977; 20: 680–88.
5 Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic 
intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma 
between the ages of 20– 69: an autopsy study of 249 cases. In Vivo 
1994; 8: 439–43.
6 Kattan MW, Eastham J. Algorithms for prostate-speciﬁ c antigen 
recurrence after treatment of localized prostate cancer. 
Clin Prostate Cancer 2003; 1: 221–26.
7 Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative 
nomogram predicting the 10-year probability of prostate cancer 
recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005–12.
Articles
www.thelancet.com/oncology   Vol 12   March 2011 255
8 Kattan MW, Vickers AJ, Yu C, et al. Preoperative and postoperative 
nomograms incorporating surgeon experience for clinically 
localized prostate cancer. Cancer 2009; 115: 1005–10.
9 Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated 
catalog of prostate cancer predictive tools. Cancer 2008; 113: 3075–99.
10 Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. 
Biochemical (prostate speciﬁ c antigen) recurrence probability 
following radical prostatectomy for clinically localized prostate 
cancer. J Urol 2003; 169: 517–23.
11 Capitanio U, Briganti A, Gallina A, et al. Predictive models before 
and after radical prostatectomy. Prostate 2010; 70: 1371–78.
12 Tewari A, Johnson CC, Divine G, et al. Long-term survival 
probability in men with clinically localized prostate cancer: 
a case-control, propensity modeling study stratiﬁ ed by race, age, 
treatment and comorbidities. J Urol 2004; 171: 1513–19.
13 Kattan MW, Cuzick J, Fisher G, et al. Nomogram incorporating PSA 
level to predict cancer-speciﬁ c survival for men with clinically 
localized prostate cancer managed without curative intent. Cancer 
2008; 112: 69–74.
14 Nakagawa T, Kollmeyer TM, Morlan BW, et al. A tissue biomarker 
panel predicting systemic progression after PSA recurrence 
post-deﬁ nitive prostate cancer therapy. PLoS One 2008; 3: e2318.
15 Kosari F, Munz JM, Savci-Heijink CD, et al. Identiﬁ cation of 
prognostic biomarkers for prostate cancer. Clin Cancer Res 2008; 
14: 1734–43.
16 Glinsky GV, Glinskii AB, Stephenson AJ, Hoﬀ man RM, Gerald WL. 
Gene expression proﬁ ling predicts clinical outcome of prostate 
cancer. J Clin Invest 2004; 113: 913–23.
17 Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identiﬁ es 
a death-from-cancer signature predicting therapy failure in patients 
with multiple types of cancer. J Clin Invest 2005; 115: 1503–21.
18 Singh D, Febbo PG, Ross K, et al. Gene expression correlates 
of clinical prostate cancer behavior. Cancer Cell 2002; 1: 203–09.
19 Lapointe J, Li C, Higgins JP, et al. Gene expression proﬁ ling 
identiﬁ es clinically relevant subtypes of prostate cancer. 
Proc Natl Acad Sci USA 2004; 101: 811–16.
20 Yu YP, Landsittel D, Jing L, et al. Gene expression alterations 
in prostate cancer predicting tumor aggression and preceding 
development of malignancy. J Clin Oncol 2004; 22: 2790–99.
21 Cheang MC, van de Rijn M, Nielsen TO. Gene expression proﬁ ling 
of breast cancer. Annu Rev Pathol 2008; 3: 67–97.
22 van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression 
signature as a predictor of survival in breast cancer. N Engl J Med 
2002; 347: 1999–2009.
23 Wang Y, Klijn JG, Zhang Y, et al. Gene-expression proﬁ les to predict 
distant metastasis of lymph-node-negative primary breast cancer. 
Lancet 2005; 365: 671–79.
24 Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, 
and integration of a wound-response gene expression signature in 
predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 
102: 3738–43.
25 Sotiriou C, Desmedt C. Gene expression proﬁ ling in breast cancer. 
Ann Oncol 2006; 17 (suppl 10): x259–62.
26 Sotiriou C, Wirapati P, Loi S, et al. Gene expression proﬁ ling in 
breast cancer: understanding the molecular basis of histologic grade 
to improve prognosis. J Natl Cancer Inst 2006; 98: 262–72.
27 Paik S, Shak S, Tang G, et al. A multigene assay to predict 
recurrence of tamoxifen-treated, node-negative breast cancer. 
N Engl J Med 2004; 351: 2817–26.
28 Fan C, Oh DS, Wessels L, et al. Concordance among 
gene-expression-based predictors for breast cancer. N Engl J Med 
2006; 355: 560–69.
29 Mosley JD, Keri RA. Cell cycle correlated genes dictate the 
prognostic power of breast cancer gene lists. BMC Med Genomics 
2008; 1: 11.
30 Whitﬁ eld ML, Sherlock G, Saldanha AJ, et al. Identiﬁ cation of 
genes periodically expressed in the human cell cycle and their 
expression in tumors. Mol Biol Cell 2002; 13: 1977–2000.
31 Cuzick J, Fisher G, Kattan MW, et al. Long-term outcome among 
men with conservatively treated localised prostate cancer. 
Br J Cancer 2006; 95: 1186–94.
32 Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer 
incidence in ﬁ ve continents. IARC scientiﬁ c publication number 155. 
Lyon: International Agency for Research and Cancer, 2002.
33 Swanson GP, Riggs M, Hermans M. Pathologic ﬁ ndings at radical 
prostatectomy: risk factors for failure and death. Urol Oncol 2007; 
25: 110–14.
34 Berney DM, Gopalan A, Kudahetti S, et al. Ki-67 and outcome in 
clinically localised prostate cancer: analysis of conservatively treated 
prostate cancer patients from the Trans-Atlantic Prostate Group 
study. Br J Cancer 2009; 100: 888–93.
35 Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based 
survival prediction in lung adenocarcinoma: a multi-site, blinded 
validation study. Nat Med 2008; 14: 822–27.
36 Zhang J, Liu B, Jiang X, et al. A systems biology-based gene 
expression classiﬁ er of glioblastoma predicts survival with solid 
tumors. PLoS One 2009; 4: e6274.
